Clinical Trials Logo

Hypoactive Delirium clinical trials

View clinical trials related to Hypoactive Delirium.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02899156 Terminated - Hypoactive Delirium Clinical Trials

Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure

FLYP
Start date: March 2016
Phase: Phase 4
Study type: Interventional

Delirium within the intensive care unit (ICU) is associated with poor outcomes such as increased mortality, ICU and hospital length of stay (LOS), and time on mechanical ventilation. Benzodiazepine (BZD) exposure is an independent risk factor for development of delirium. Reversal of hypoactive delirium represents a potential opportunity for reducing duration of delirium and subsequent complications. This is a single-center randomized, double-blind, placebo-controlled study of critically ill adult patients with benzodiazepine-associated hypoactive delirium. The hypothesis is that flumazenil continuous infusion may reverse hypoactive delirium associated with BZD exposure and thereby reduce duration of delirium and ICU LOS.